Acrivon Therapeutics

IPO

Precision oncology powered by proteomics

Public · Watertown, United States · Founded 2018 · $230.0M raised

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$230.0M
Last Round
$130.0M Venture RoundApr 2024
Rounds
2
Type
Public

About

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision oncology medicines utilizing its proprietary Acrivon Precision Predictive Proteomics (AP3) platform. The AP3 platform enables unprecedented patient selection by profiling the activity of key cancer-driving proteins at the individual tumor level, identifying which patients are most likely to respond to a given targeted therapy. Headquartered in Watertown, Massachusetts, Acrivon is advancing a pipeline of precision oncology drug candidates, including ACR-368, a CHK1/2 inhibitor being evaluated in endometrial and ovarian cancers.

Summary

Acrivon Therapeutics is a Biotech company based in Watertown, United States, founded in 2018. It has raised $230.0M in total across 2 rounds, most recently a $130.0M Venture Round round in Apr 2024. Investors include Morgan Stanley, Jefferies and Cowen.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture UnknownApr 2024
$130.0M

Sign up to see all 3 rounds

Series B through Venture Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Acrivon Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/acrivon-therapeutics"><img src="https://indexed.vc/api/badge/company/acrivon-therapeutics" alt="Acrivon Therapeutics on Indexed.vc" width="260" height="76" /></a>